Answers are grounded in this paper and cite their sources.
Randomized control trials (RCTs) are required before drug and device approvals and have contributed to patient safety, but they have also increased the cost and time of regulatory assessments. We propose that using real-world evidence to complement or, in some settings, to replace RCTs will accelerate delivery of new drugs to patients.
No takes yet. Share an insight, caveat, or question.
Raoof et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: